Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the need for septal reduction therapy (SRT) among patients with obstructive hypertrophic cardiomyopathy (HCM). Results of the study, which were presented at the European Society of Cardiology (ESC) Congress 2023, indicate the rate of SRT or SRT eligibility in the placebo-crossover group was more than twice that of the mavacamten only arm, with use of mavacamten also associated with improvements in resting and Valsalva left ventricular outflow tract (LVOT) gradients. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more